Skip to main content

Table 3 Patient Stratification by Ethnicity

From: Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study

  # of Patients (%)
Characteristic Hispanic NH P Value
Age (yrs) (n = 86)    1
   <60 49 (92.5%) 30 (90.9%)  
   >/=60 4 (7.5%) 3 (9.1%)  
Gender (n = 87)    0.19
   Female 23 (43.4%) 20 (58.8%)  
   Male 30 (56.6%) 14 (41.2%)  
Hemoglobin (g/dL) (n = 83)    1
   <12 34 (68%) 23 (69.7%)  
   >/=12 16 (32%) 10 (30.3%)  
Leukocyte count (× 109/L) (n = 85)    0.13
   <50 10 (10.6%) 12 (35.3%)  
   >/=50 41 (80.4%) 22 (64.7%)  
Platelets (× 109/L) (n = 82)    0.64
   <450 29 (58%) 21 (65.6%)  
   >/=450 21 (42%) 11 (34.4%)  
Hasford Score (n = 64)    0.046
   </=780 low-risk 23 (56.1%) 12 (52.2%)  
   >780 and </=1480 intermediate 16 (39.0%) 5 (21.7%)  
   >1480 high-risk 2 (4.9%) 6 (26.1%)  
Sokal Score (n = 65)    0.11
   <0.8 good prognosis 19 (45.2%) 6 (26.1%)  
   0.8–1.2 moderate prognosis 16 (38.1%) 8 (34.8%)  
   >1.2 poor prognosis 7 (16.7%) 9 (39.1%)  
CHR at 3 months, all treatments (n = 47)    0.016
   Yes 20 (76.9%) 8 (38.1%)  
   No 6 (23.1%) 13 (61.9%)  
CHR at 3 months, imatinib only (n = 36)    0.23
   Yes 19 (82.6%) 8 (61.5%)  
   No 4 (17.4%) 5 (38.5%)  
  1. Selected demographic and clinical features of CML patients are presented, stratified by ethnicity.